Trials / Active Not Recruiting
Active Not RecruitingNCT06373146
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 392 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Mibavademab | Administered SC |
| DRUG | Tirzepatide-Placebo | Administered SC |
| DRUG | Mibavademab-Placebo | Administered SC |
Timeline
- Start date
- 2024-04-24
- Primary completion
- 2025-12-15
- Completion
- 2026-04-01
- First posted
- 2024-04-18
- Last updated
- 2026-01-22
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06373146. Inclusion in this directory is not an endorsement.